Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
April 13, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
April 11, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
March 22, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated Phase 1a Clinical Trial for NXP800 Announced Promising Data for NXP900 in Triple Negative...
Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
March 10, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for...
Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
March 09, 2022 10:12 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
February 22, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Data Published in Cancer Research, a journal of the American Association for Cancer Research Publication highlights potent activity of NXP900, a differentiated inhibitor of the SRC/YES1 Kinases ...
Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock
February 08, 2022 13:00 ET
|
Nuvectis Pharma, Inc.
New York, NY, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis”), a biopharmaceutical company that focuses on the development of innovative precision medicines for...
Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
February 04, 2022 09:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800
December 31, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , Dec. 31, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
September 14, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious...